Vaccine manufacturer Moderna said Wednesday the US Food and Drug Administration walked back its previous position and agreed to review the company's new mRNA-based flu shot. Last week the US firm said ...
An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results